National Pharmacy Association (NPA) - News updates

Certain pages on this news feed are only available to NPA members and hence requires members to log-in accordingly


Class 4 drug alert – Ibuprofen tablets 400mg Crescent Pharma Ltd and Flamingo Pharma (UK) Ltd

Ref: EL (20)A/10 20 February 2020 A Class 4 drug alert has been issued by the Medicines & Healthcare products Regulatory Agency (MHRA).  Crescent Pharma Ltd and Flamingo Pharma (UK) Ltd have informed the MHRA that the Patient Information Leaflet (PIL) for specific batches of Ibuprofen tablets 400mg is incorrect Further information can be found on the MHRA section on the GOV.UK website. Produced by the NPA Pharmacy Services team February 2020…

Can’t find what you’re looking for on the NPA website?

Displaying COVID-19 posters – advice for pharmacy teams

Public Health England (PHE) are advising pharmacies to prominently display the following two posters so that they can clearly be seen by patients wishing to enter the pharmacy premises: Poster for outside pharmacies, GPs and other NHS settings Affected countries and places poster Additional PHE posters including COVID-19 public information and home isolation advice are available on the NPA website The NPA has published a dedicated webpage to COVID-19 with country specific posters. The following resources have also been produced to support pharmacy teams in the provision of advice for patients wanting more information on COVID-19: COVID-19 – pharmacy team guide: this details the signs and symptoms of COVID-19 and provides advice for pharmacy teams COVID-19 – poster for pharmacy teams: a quick go-to guide for pharmacy teams to prevent the risk of infection For further information please contact the NPA Pharmacy Services team on 01727 891800 or email at: pharmacyservices@npa.co.uk. Produced by the NPA Pharmacy Services team February 2020.…

Price Concessions – February 2020

Drug Price Concession Co-careldopa tablets 25mg/100mg (100) £11.98 Fluoxetine capsules 10mg (30) £46.89 Frovatriptan tablets 2.5mg (6) £10.18 Hydroxyzine tablets 10mg (84) £2.10 Hydroxyzine tablets 25mg (28) £0.90 Irbesartan tablets 150mg (28) £5.00 Irbesartan 300mg / Hydrochlorothiazide 12.5mg tablets (28) £4.74 Meloxicam tablets 15mg (30) £5.71 Memantine tablets 10mg (28) £2.65 Memantine tablets 20mg (28) £7.40 Nitrazepam tablets 5mg (28) £3.10 Quinine sulfate tablets 300mg (28) £6.99 Rivastigmine capsules 3mg (28) £3.95…

National clinical audit topic announced for 2019/20 – Antimicrobial stewardship

All community pharmacy contractors must participate in the annual national clinical audit during March 2020 as part of the Community Pharmacy Contractual Framework (CPCF) requirements. The agreed national audit by the Pharmaceutical Services Negotiating Committee (PSNC) and the NHSE&I for 2019/20, will concentrate on antimicrobial stewardship by provision of clinically suitable advice to patients seeking information on the management of upper respiratory tract infection (URTI) symptoms. The audit must be conducted in March 2020 (finishing no later than 31 March) over a consecutive period of five days, collecting data from a minimum of 10 patients. For full guidance and actions for pharmacy contractors on completing the audit, refer to the “2019/20 Community Pharmacy Contractual Framework national clinical audit: Antimicrobial stewardship” For further information on this or any other query, please contact the NPA Pharmacy Services team on 01727 891 800 or email pharmacyservices@npa.co.uk. Produced by the NPA Pharmacy Services team February 2020.…

Get involved in the MHRA Yellow Card ADR awareness week 17-24 February 2020

The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a week long social media campaign focusing on polypharmacy and reporting adverse drug reactions (ADR) to ensure patient safety. What is polypharmacy? Polypharmacy is concurrent use of four or more medicines at the same time; this includes prescription only medicines (POM), pharmacy medicines, over the counter (OTC) sales and traditional medicines. Patients taking multiple medicines are at increased risk of getting side effects and interactions between medicines. Healthcare professionals including community pharmacists are encouraged to raise awareness and review patient’s taking multiples medicines. The Yellow Card Scheme is an essential tool that the MHRA uses to monitor the safety of medicines, medical devices and herbal or complimentary medicines. It is crucial to report problems with these products in order to improve patient safety by identifying issues such as side effects, as well as defective and counterfeit medicines or medical devices. How can you support the campaign? Share campaign content through social media Follow the MHRA twitter feed and other social media channels like Facebook, LinkedIn and Instagram Provide feedback to the MHRA from the feedback you have generated Contact the MHRA for further information about the Yellow Card Scheme including yellow card website logo, paper reporting forms and stickers Email details to jadeja@mhra.gov.uk For further information on this or any other query, please contact the NPA Pharmacy Services team on 01727 891 800 or email pharmacyservices@npa.co.uk.…

Class 4 medicines defect information – Caution in Use – Diamorphine Hydrochloride BP Lyophilisate for Solution for Injection 100mg

Ref: EL (20)A/09 17 February 2020 Diamorphine Hydrochloride BP Lyophilisate for Solution for Injection 100mg (Manufactured by Accord Healthcare Ltd) PL 20075/0675 A Class 4 medicines defect information alert has been issued by the Medicines & Healthcare products Regulatory Agency (MHRA) for specific batches of Diamorphine Hydrochloride BP Lyophilisate for Solution for Injection 100mg. Accord Healthcare Ltd has informed the MHRA of a discrepancy in specific batches which does not have the expiry date encoded in 2D data matrix leading to an error message displayed upon decommissioning. Diamorphine Hydrochloride BP Lyophilisate for Solution for Injection 100mg Batch number Expiry date Pack size F19160 May 2022 1 x 5 ampoules F19161 May 2022 1 x 5 ampoules Further information can be found on the MHRA section on the GOV.UK website. Produced by the NPA Pharmacy Services team February 2020.…

NPA study to show impact of frozen funding on pharmacy’s ability to deliver for NHS

An expert team from EY will assess the robustness of the pharmacy market and consider how far restricted funding and the broader economic environment may impact on efforts to achieve NHS objectives. Literature searches, interviews with stakeholders and a comprehensive survey of NPA members will highlight current pressure points and the impact of foreseeable changes in funding and costs. EY will also explore what all this means for General Practice, hospitals, patients and wider society. The NPA expects to obtain telling evidence about the capacity of the pharmacy sector to deliver on NHS objectives, in the context of current flat funding. Speaking at the Sigma Pharmaceuticals conference today, the NPA’s Acting Chairman, Andrew Lane, said: “It’s the NPA’s duty, as the voice of independent community pharmacy, to speak out passionately but also factually. Therefore we have secured the expert services of EY to deliver a detailed financial and operational analysis of the current and future position for independent pharmacies. “Ministers and NHS officials say they want community pharmacies to be the first port of call for common illnesses, to help people stay well, to take on more clinical services and to relieve pressure on other parts of the system. This can only be achieved on a sustainable basis if resources match the level of ambition.…

Adrenaline — urgent patient safety update and reminder on ordering process for EpiPen®, and stock availability – UPDATED FEBRUARY 2020

Coronavirus disease 2019: Are you up to date with the latest advice?

The World Health Organisation (WHO) has now named the Wuhan novel coronavirus COVID-19, short for “coronavirus disease 2019.” The risk associated with COVID-19 remains a high priority patient safety concern and we would like to highlight recent updates and additional guidance to support you and your pharmacy team when faced with questions from the public or when presented with a suspected case of the disease. Coronaviruses are a large family of viruses and there are several known coronaviruses that infect people and usually only cause mild respiratory disease, such as the common cold. However, at least two previously identified coronaviruses have caused severe disease – Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). The route of transmission is unknown, however transmission of other coronaviruses is typically through direct or indirect contact with infected respiratory secretions as well as blood, faeces and urine. Symptoms of COVID-19 People with underlying illnesses such as asthma, diabetes, weakened immune systems and the elderly are likely to be more vulnerable to respiratory disease. The majority of infected people report a mild illness, however there are some cases where severe symptoms have been reported and also a small number of fatalities. Symptoms of COVID-19 may include: ·         Fever ·         Cough ·         Tightness of the chest ·         Sore throat ·         Nasal congestion ·         Malaise ·         Headache ·         Muscle pain ·         Dyspnoea (difficulty in breathing) ·         Pneumonia ·         Severe respiratory syndrome Treatment and Prevention Currently, there is no specific, antiviral treatment available although treatment should be given to patients infected with COVID-19 to relieve symptoms.…